Who
Michael F. MacLean
Director
Company insider
Files Form 4 as: Director, CAMP4 Therapeutics; Chief Financial Officer, Avidity Biosciences; Director, Verve Therapeutics; Chief Financial Officer, Akcea Therapeutics; SVP, Chief Accounting Officer, Biogen.
In numbers
- Trades disclosed
- 127
- Buys
- 0
- Sells
- 21
- Bought
- $0
- Sold
- $17.1M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 12 Feb 2007
- Last trade
- 1 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 3 Apr 2026 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —133,977 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —92,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —131,250 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —92,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —131,250 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —148,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —60,125 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —106,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —148,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —60,125 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —106,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciences | SEC FORM 4 Code D | —133,977 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Sold | $131K1,807 at $72.45 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Sold | $198K2,735 at $72.45 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity Biosciences | SEC FORM 4 Sold | $131K1,807 at $72.45 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity Biosciences | SEC FORM 4 Sold | $198K2,735 at $72.45 | filing |
News
Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst UpgradeBIIB · dailypolitical.com · 14 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?BIIB · insidermonkey.com · 13 Oct 2026Biogen (NASDAQ:BIIB) Stock Price Target Cut by Royal Bank Of CanadaBIIB · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Michael F. MacLean; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.